REVIEW ARTICLE
Year : 2017 | Volume
: 3 | Issue : 1 | Page : 18--21
Cardiology update 2017: The first quarter
Sridharan Umapathy
Department of Cardiology, AIIMS, New Delhi, India
Correspondence Address:
Sridharan Umapathy
Department of Cardiology, AIIMS, New Delhi
India
In the first quarter of 2017, proprotein convertase subtilisin/kexin type 9's role got defined further with a number of trials such as FOURIER, ORION-1, and SPIRE 1 and 2. TAVI proves safe in intermediate-risk patients in the Surgical Replacement and Transcatheter Aortic Valve Implantation study. Newer anticoagulants extended their role to valvular heart disease. Bioabsorbable stent showed problems (ABSORB 2 and 3). New guidelines have been released for syncope and transcatheter aortic valve replacement implantation. Clinical outcome studies involving instantaneous wave-free ratio (IFR) showed IFR to be noninferior to fractional flow reserve. Optimal medical therapy proves noninferior to percutaneous coronary intervention in single vessel chronic total occlusion.
How to cite this article:
Umapathy S. Cardiology update 2017: The first quarter.J Pract Cardiovasc Sci 2017;3:18-21
|
How to cite this URL:
Umapathy S. Cardiology update 2017: The first quarter. J Pract Cardiovasc Sci [serial online] 2017 [cited 2023 Feb 1 ];3:18-21
Available from: https://www.j-pcs.org/article.asp?issn=2395-5414;year=2017;volume=3;issue=1;spage=18;epage=21;aulast=Umapathy;type=0 |
|
